Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 414-420

  Leenen, Celine H M ^a   Van Lier, Margot G F ^a   Van Doorn, Helena C ^a   Van Leerdam, Monique E ^a   Kooi, Sjarlot G ^b   De Waard, Judith ^c   Hoedemaeker, Robert F ^d   Van Den Ouweland, Ans M W ^a   Hulspas, Sanne M ^a   Dubbink, Hendrikus J ^a   Kuipers, Ernst J ^a   Wagner, Anja ^a   Dinjens, Winand N M ^a   Steyerberg, Ewout W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^c Sint Franciscus Gasthuis ^*  (Netherlands)

^d Pathology Laboratory Pathan   (Netherlands)

Author keywords

Endometrial cancer; Hereditary cancer; Immunohistochemistry; Lynch syndrome; Microsatellite instability

Indexed keywords

B RAF KINASE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2;

ADULT; AGED; ARTICLE; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METHYLATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADENOSINE TRIPHOSPHATASES; AGED; CARCINOMA, ENDOMETRIOID; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MIDDLE AGED; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84859566031     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.049     Document Type: Article

References (40)

1. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-8. (Pubitemid 29144749)
2. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-60.
3. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009;10:400-8.
4. Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010;138:487-92.
5. Loukola A, Eklin K, Laiho P, Salovaara R, Kristo P, Jarvinen H, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 2001;61:4545-9. (Pubitemid 32685787)
6. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348: 919-32. (Pubitemid 36298000)
7. Burks RT, Kessis TD, Cho KR, Hedrick L. Microsatellite instability in endometrial carcinoma. Oncogene 1994;9:1163-6. (Pubitemid 24095025)
8. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100-3. (Pubitemid 23333372)
9. Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, et al. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res 2004; 10:481-90. (Pubitemid 38173986)
10. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999;8:661-6. (Pubitemid 29139981)
11. de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006;130:665-71. (Pubitemid 43374516)
12. Jarvinen HJ, Aarnio M. Surveillance on mutation carriers of DNA mismatch repair genes. Ann Chir Gynaecol 2000;89:207-10.
13. Stupart DA, Goldberg PA, Algar U, Ramesar R. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis 2009;11:126-30.
14. Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary nonpolyposis colorectal cancer. Nat Rev Cancer 2004;4:153-8. (Pubitemid 38198743)
15. VasenHF,Watson P,Mecklin JP, LynchHT. Newclinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-6. (Pubitemid 29258894)
16. Ramsoekh D, Wagner A, van Leerdam ME, Dinjens WN, Steyerberg EW, Halley DJ, et al. A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Gut 2008;57:1539-44.
17. Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000;37:641-5.
18. van Lier MG, Wagner A, van Leerdam ME, Biermann K, Kuipers EJ, Steyerberg EW, et al. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med 2010;14:181-97.
19. van der Klift HM, Tops CM, Bik EC, Boogaard MW, Borgstein AM, Hansson KB, et al. Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients. Hum Mutat 2010;31:578-87.
20. Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997;277:915-9. (Pubitemid 27123953)
21. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-9. (Pubitemid 43113031)
22. Klarskov L, Ladelund S, Holck S, Roenlund K, Lindebjerg J, Elebro J, et al. Interobserver variability in the evaluation of mismatch repair protein immunostaining. Hum Pathol 2010;41:1387-96.
23. Zauber NP, Denehy TR, Taylor RR, Ongcapin EH, Marotta SP, Sabbath-Solitare M, et al. Microsatellite instability and DNA methylation of endometrial tumors and clinical features in young women compared with older women. Int J Gynecol Cancer 2010;20:1549-56.
24. Feng YZ, Shiozawa T, Miyamoto T, Kashima H, Kurai M, Suzuki A, et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 2005;11: 6133-8. (Pubitemid 41262939)
25. Salvesen HB, Kumar R, Stefansson I, Angelini S, MacDonald N, Smeds J, et al. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer 2005;115:930-4. (Pubitemid 40791834)
26. Kawaguchi M, Yanokura M, Banno K, Kobayashi Y, Kuwabara Y, Kobayashi M, et al. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. Int J Oncol 2009;34:1541-7.
27. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810-7. (Pubitemid 44289242)
28. Backes FJ, Leon ME, Ivanov I, Suarez A, Frankel WL, Hampel H, et al. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecol Oncol 2009;114:486-90.
29. Backes FJ, Mitchell E, Hampel H, Cohn DE. Endometrial cancer patients and compliance with genetic counseling: room for improvement. Gynecol Oncol 2011;123(3):532-6.
30. Black D, SoslowRA, Levine DA, Tornos C, Chen SC, Hummer AJ, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006;24:1745-53. (Pubitemid 46622146)
31. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003;100:5908-13. (Pubitemid 36576906)
32. Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 2007;25:5158-64. (Pubitemid 350232246)
33. Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol 2007;31:744-51. (Pubitemid 46684215)
34. Ollikainen M, Abdel-Rahman WM, Moisio AL, Lindroos A, Kariola R, Jarvela I, et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol 2005;23:4609-16. (Pubitemid 46224063)
35. Erfelijke Darmkanker Richtlijn. Vereniging Klinische Genetica Nederland; Kwaliteitsinstituut voor de gezondheidszorg CBO; 2008.
36. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007;107:159-62. (Pubitemid 47575743)
37. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011;29(16):2247-52.
38. Backes FJ, Hampel H, Backes KA, Vaccarello L, Lewandowski G, Bell JA, et al. Are prediction models for Lynch syndrome valid for probands with endometrial cancer? Fam Cancer 2009;8:483-7.
39. de Leeuw WJ, Dierssen J, Vasen HF, Wijnen JT, Kenter GG, Meijers-Heijboer H, et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 2000;192:328-35.
40. Walsh CS, Blum A, Walts A, Alsabeh R, Tran H, Koeffler HP, et al. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. Gynecol Oncol 2010;116:516-21.